Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, gives an update on the Phase I monotherapy cohort of the TRANSCEND CLL 004 study (NCT03331198), investigating lisocabtagene maraleucel (liso-cel) as a treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The follow-up study reported that liso-cel induced durable responses in many patients. At 18-months follow-up, the median duration of response had not been reached. High rates of undetectable measurable residual disease were observed, indicating deep remission in these patients. Liso-cel was still detectable in treated patients for up to 18 months post-infusion and no late or delayed adverse effects of concern emerged. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.